London-based Blue Beagle Bio secures £208k for gene-synthesis platform

A novel gene-synthesis platform being developed by Blue Beagle Bio Ltd has been backed by a fresh investment of approximately £208.1k. Based in London, the company reached an estimated post-money valuation of £1.7m through this capital raise. The business was incorporated in 2022 to address the specific requirements of researchers and biotechnology firms that need DNA constructs for scientific and product-development work.

The technology is designed to deliver these constructs more quickly and at a lower cost than existing synthesis methods. Financial filings for the fiscal year ended 30 September 2025 indicate that the company maintains a headcount of one person, a figure mirrored by its professional networking profiles.

The investment follows an allotment of shares in August 2026. Formal documentation regarding the transaction was filed in September 2026.